Search Result

Results for "

Biofilms,Rodent models,Toxicological synergy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (3) Bacterial (1) Bcl-2 Family (1) CDK (2) EGFR (1) ERK (1) Fungal (1) Guanylate Cyclase (1) HIF/HIF Prolyl-Hydroxylase (1) Microtubule/Tubulin (1) mTOR (1) NOD-like Receptor (NLR) (1) PARP (1) PI3K (1) Survivin (1) Toll-like Receptor (TLR) (1) Virus Protease (1) WDR5 (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (1) Infection (5) Inflammation/Immunology (3)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12376

BAY 41-2272 3 Publications Verification	Guanylate Cyclase	Inflammation/Immunology
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research .

HY-139287

M1002 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .

HY-153384

EAPB 02303	Microtubule/Tubulin Apoptosis	Cancer
EAPB 02303 is a microtubule-disrupting agent and inhibitor. EAPB 02303 induces mitosis arrest and impairment of spindle assembly. Thus, EAPB 02303 induces apoptosis and exhibits antitumor activity. EAPB 02303 also exhibits a potent synergy with Paclitaxel (HY-B0015) at lower concentrations .

HY-136555

GSK717 5+ Cited Publications	NOD-like Receptor (NLR)	Inflammation/Immunology
GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC₅₀ of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-130250

SR-4835 Maximum Cited Publications 12 Publications Verification	CDK Apoptosis	Cancer
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC₅₀=99 nM, K_d=98 nM; CDK13: K_d=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death .

HY-103484

GATA4-NKX2-5-IN-1	Others	Cardiovascular Disease
GATA4-NKX2-5-IN-1 (Compound 3) dose-dependently inhibits the GATA4–NKX2-5 transcriptional synergy with an IC₅₀ of 3 μM. GATA4-NKX2-5-IN-1 exhibits no activity on the protein kinases involved in the regulation of GATA4 phosphorylation, and it modulates the hypertrophic agonist-induced cardiac gene expression .

HY-162281

PROTAC SOS1 degrader-6	Others	Cancer
PROTAC SOS1 degrader-6 (compound 23) is a potent SOS1 PROTACs degrader with synergistic efficacy with KRAS ^G12C inhibitors .

HY-W689801

A-1208746	Bcl-2 Family Apoptosis	Cancer
A-1208746 is an inhibitor for MCL-1, with a K_i of 0.454 nM. A-1208746 activates caspase-3/-7, induces apoptosis in cell H929, and decreases mitochondrial membrane potential. A-1208746 synergies with Navitoclax (HY-10087), and can be used in cancer research .

HY-162859

AB25583	Others	Cancer
AB25583 is a Polθ helicase (Polθ-hel) small molecule inhibitor, with an IC₅₀ value of 6 nM. AB25583 selectively kills BRCA1/2 deficient cells and works in synergy with Olaparib (HY-10162) in cancer cells carrying pathogenic BRCA1/2 mutations. AB25583 can be used for tumor research .

HY-125390

SM-360320 CL-087	Toll-like Receptor (TLR)	Inflammation/Immunology
SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response . SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity .

HY-15882

GNE-783	Others	Cancer
GNE-783 is a selective CHK1 inhibitor that enhances the activity of gemcitabine. GNE-783 improves the efficacy of anti-metabolite DNA damage drugs by inactivating S-phase and G2-phase cell cycle checkpoints following DNA damage. GNE-783 selectively enhances the chemical synergy of certain drugs in different tumor types, for example, enhancing the activity of temozolomide only in melanoma cell lines .

HY-161380

Antifungal agent 96	Fungal	Infection
Antifungal agent 96 (Compound WZ-2) is an antifungal agent with good blood-brain barrier permeability and brain penetration. Antifungal agent 96 inhibits the growth of C. neoformans H99 and C. albicans 0304103 with MIC values of 0.016 and 32 μg/mL, respectively .

HY-154949

WDR5-IN-6	WDR5	Cancer
WDR5-IN-6 is a WDR5 inhibitor, targeting to WBM site. WDR5-IN-6 inhibits cell proliferation of neuroblastoma cell lines with potent anti-tumor activity. WDR5-IN-6 shows high synergy with OICR-9429 (HY-16993), a WDR5 inhibitor targeting to WIN site. WDR5-IN-6 can be used for reasearch in neuroblastoma .

HY-19476

AG-7404	Virus Protease	Infection
AG-7404 is an inhibitor of picornaviral 3C protease, with anti-poliovirus activity (EC₅₀=0.080-0.674 μM). AG-7404 has synergy with V-073 (HY-104074) or BTA798 (HY-106254), and fully inhibits all V-073-resistant variants . AG-7404 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-158106

AZD8421	CDK	Cancer
AZD8421 is a selective CDK2 inhibitor (IC₅₀: 9 nM) with selectivity for CDK1, CDK4 and CDK6. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest and senescence. AZD8421 demonstrated promising single efficacy and synergy with CDK4/6 inhibitors such as Palbociclib (HY-50767) in in vivo breast and ovarian models. AZD8421 also has potent single-agent inhibitory activity against drug-resistant breast cancer cells.

HY-162382

KTC1101	PI3K Akt mTOR	Cancer
KTC1101 is an orally active pan-PI3K inhibitor. KTC1101 can inhibit the PI3K signaling pathway, reduce downstream AKT and mTOR phosphorylation, and reduces the expression of Ki67. The anti-tumor effect of KTC1101 has a dual mechanism of action: directly inhibiting tumor cell growth and dynamically enhancing immune response .

HY-161823

Anti-MRSA agent 13	Bacterial	Infection
Anti-MRSA agent 13 (Compound 9b) is an agent against methicillin-resistant Staphylococcus aureus (MRSA), exhibiting a minimum inhibitory concentration (MIC) of 0.5–2 μg/mL against clinically isolated MRSA strains. Anti-MRSA agent 13 possesses favorable biosafety, plasma tolerance stability, and a low tendency to develop resistance. Anti-MRSA agent 13 disrupts cell walls and membranes, reduces metabolic activity, causes oxidative damage, affects DNA function, and ultimately leads to MRSA death through multi-target synergies .

HY-118487A

OB-24 free base	Others	Cancer
OB-24 free base is a compound that potently and selectively inhibits heme oxygenase 1 (HO-1) and has the potential to inhibit advanced prostate cancer. OB-24 significantly reduces protein carbonylation and the formation of reactive oxygen species by selectively inhibiting HO-1 activity in prostate cancer cells. OB-24 significantly inhibited cell proliferation in vitro and inhibited tumor growth and lymph node and lung metastasis in vivo. OB-24 exhibits powerful synergy when used in combination with Taxol .

HY-114216

DBPR110	Others	Infection
DBPR110 is a nonstructural protein 5A (NS5A) inhibitor with inhibitory activity against hepatitis C virus (HCV). DBPR110 exhibited a 50% effective concentration (EC50) of 3.9 ± 0.9 pM and a selectivity index value of over 12,800,000 by reducing HCV1b replicon reporter expression. DBPR110 also effectively reduced the activity of HCV2a replicon with an EC50 of 228.8 pM and a selectivity index value of over 173,130. DBPR110 showed synergy with interferon alpha (IFN-α), NS3 protease inhibitors, and NS5B polymerase inhibitors. The results of DBPR110 suggest that it may be an effective small molecule inhibitor against HCV NS5A .

Cat. No.	Product Name	Target	Research Area

HY-P99277

Actoxumab Anti-C. difficile Toxin A Recombinant Antibody	Inhibitory Antibodies	Infection
Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	EGFR Akt ERK PARP Survivin
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

Cat. No.	Product Name		Classification

HY-19476

AG-7404		Alkynes
AG-7404 is an inhibitor of picornaviral 3C protease, with anti-poliovirus activity (EC₅₀=0.080-0.674 μM). AG-7404 has synergy with V-073 (HY-104074) or BTA798 (HY-106254), and fully inhibits all V-073-resistant variants . AG-7404 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Biofilms,Rodent models,Toxicological synergy

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Natural
Products